Displaying One Session

AstraZeneca - Redefining long-term outcomes in newly diagnosed advanced ovarian cancer: Expert perspectives on integrating personalized medicine (ID 125)

Time
08:45 - 10:15

Key considerations for treatment of newly diagnosed advanced ovarian cancer (ID 4753)

Implementing Personalized Medicine: Evidence review and patient case based discussions - HRD positive: BRCA 1/2 mutation (ID 4754)

Implementing Personalized Medicine: Evidence review and patient case based discussions - HRD Positive: no BRCA mutation, high genomic instability score (ID 4755)

Implementing Personalized Medicine: Evidence review and patient case based discussions - HRD Negative: Low genomic instability score (ID 4756)

Future Perspectives (ID 4757)

Panel Discussion and Q&A (ID 4758)